Franklin Resources Inc. Has $15.26 Million Stock Position in ABIVAX Société Anonyme (NASDAQ:ABVX)

Franklin Resources Inc. trimmed its position in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 5.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,324,352 shares of the company's stock after selling 70,700 shares during the period. Franklin Resources Inc. owned approximately 2.09% of ABIVAX Société Anonyme worth $15,257,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABVX. Point72 Asset Management L.P. lifted its holdings in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock valued at $6,254,000 after purchasing an additional 119,300 shares during the last quarter. abrdn plc raised its holdings in shares of ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company's stock valued at $3,645,000 after acquiring an additional 198,225 shares during the period. Walleye Capital LLC lifted its position in shares of ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock valued at $2,965,000 after acquiring an additional 80,807 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock worth $150,000 after purchasing an additional 5,900 shares during the period. 47.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on ABVX. Citizens Jmp raised ABIVAX Société Anonyme to a "strong-buy" rating in a research report on Wednesday, December 4th. JMP Securities assumed coverage on shares of ABIVAX Société Anonyme in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $33.00 target price for the company. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, ABIVAX Société Anonyme has an average rating of "Buy" and a consensus target price of $38.67.

ABIVAX Société Anonyme Stock Performance

Shares of NASDAQ:ABVX traded down $0.11 on Friday, hitting $7.65. 258,030 shares of the company were exchanged, compared to its average volume of 95,833. ABIVAX Société Anonyme has a one year low of $7.11 and a one year high of $17.02. The company's 50 day moving average price is $9.31 and its two-hundred day moving average price is $11.14.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.